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Abstract
Background: Stavudine is no longer recommended as part of first-line therapy for patients initiating antiretroviral
therapy (ART) in Uganda. Most patients are currently initiated on zidovudine-containing regimens, which can
induce anaemia. We investigated the risk factors for early severe anaemia in the first six months of ART initiation.
Methods: We defined baseline (ART initiation) anaemia as haemoglobin (Hb) ≤9.5 g/dL, baseline severe anaemia
as Hb ≤8 g/dL, and early severe anaemia as Hb ≤8 g/dL within six months of ART initiation. Risk factors for the
development of early severe anaemia were analyzed using a multivariable logistic regression model.
Results: In total, 5494 patients initiated ART, 821 (15%) had baseline anaemia, and 296 (5%) had baseline severe
anaemia. Early severe anaemia occurred in 109 (4%) of 3105 patients who had at least one Hb measurement in the
first six months on ART. Patients with baseline anaemia had a larger increase in Hb (median g/dL [IQR]) within the
first six months compared with non-anaemic patients (2.9 [1.7, 4.6] vs. 0.7 [-0.2, 1.7], p < 0.0001). Having a new
tuberculosis episode OR 3.69 (95% CI 1.64 - 8.32), MCV <80fL OR 1.60 (95% CI 1.01- 2.52) and baseline severe
anaemia OR 5.27 (95% CI 3.00 - 9.26) were associated with early severe anaemia. Initiation on a zidovudine-based
regimen was not associated with an increased risk of early severe anaemia.
Conclusions: Among patients in an urban HIV clinic in Uganda, severe anaemia is modestly prevalent at ART
initiation and improves with ART in the majority of patients. These data suggest that baseline severe anaemia
should not be used as a criterion for avoiding the use of zidovudine in patients initiating ART in resource-limited
settings.
Background
Anaemia is a common condition in HIV-infected
patients [1]. Before the introduction of antiretroviral
therapy (ART), the prevalence of anaemia (defined as a
haemoglobin level of less than 10 g/dL) ranges from 15%
in asymptomatic patients to 50% in patients with a diag-
nosis of AIDS [1]. In addition, anaemia increases the risk
for both morbidity and mortality in HIV cohorts [2-6].
Reports from the post-ART era in developed countries
have shown substantial increases in mean haemoglobin
(Hb) levels after ART initiation [7,8]. Although patients
from resource-limited settings have lower baseline Hb
levels compared with patients in studies conducted in
resource-rich regions, the association between ART and
the correction of pre-existing anaemia still holds [9-12].
Since 2008, stavudine (d4T) is no longer recommended
as part of first-line therapy for patients initiating ART in
Uganda due to short- and long-term toxicity [13]. At pre-
sent, the recommended regimen is zidovudine (AZT) or
tenofovir (TDF) plus lamivudine (3TC) plus a non-
nucleoside reverse transcriptase inhibitor (NNRTI). How-
ever, due to the high cost and short supply of TDF, there
is still significant continuing d4T use, and the majority of
ART-eligible patients in Uganda are now initiated on
AZT-containing regimens [14].
AZT has been reported as a cause of hematological dis-
orders, especially anaemia [15,16], which most often
occurs within 4 to 12 weeks of AZT initiation [9,12]. As a
result of the introduction of World Health Organization
(WHO) guidelines and the Uganda National Antiretroviral
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dren (which both recommend stopping AZT in patients
whose Hb drops below 8 g/dL [17]), patients who have a
Hb count of ≤8 g/dL) and advanced disease are initiated
on TDF [18] rather than AZT, whenever possible.
The objective of our study was to analyze the risk fac-
tors for early severe anaemia, defined as Hb level ≤8g /
dL in the first six months after ART initiation, and, in
particular, to examine if AZT could be safely prescribed
to patients who initiate ART when they have baseline
severe anaemia.
Methods
Patients in this study were enrolled at the Infectious
Diseases Institute, a centre of excellence in HIV care,
treatment and research. The institute’s clinic provided
HIV-positive patients with free care and treatment, such
as: counselling; clinical care; prophylaxis for opportunistic
infections; laboratory testing, including CD4+ T cell count
measurement; and antiretroviral treatment. ART was pro-
vided by the Multi-Country HIV/AIDS Program and the
US President’s Emergency Plan for AIDS Relief, and was
prescribed according to WHO 2006 and Uganda Ministry
of Health guidelines [13,17].
The first-line ART for adults and adolescents was
d4T+3TC and nevirapine or efavirenz until March 2008
when AZT was recommended in lieu of d4T. Complete
blood counts and CD4+ counts were performed every six
months for all patients; HIV-RNA viral load measurements
were not performed routinely, but could be requested by
clinicians to confirm treatment failure. The Hb level was
obtained using a Coulter counter (ACT V) on venipunc-
ture samples.
Baseline Hb was defined as the most recent measurement
taken within three months prior to ART initiation. Baseline
anaemia was defined as Hb ≤9.5 g/dL consistent with the
ACTG, Division of AIDS, National Institutes of Health
grading [19], while baseline severe anaemia was defined as
Hb ≤8 g/dL (the criteria for AZT discontinuation in
Uganda, according to the Ministry of Health guidelines).
We analyzed the occurrence of early severe anaemia,
Hb ≤8 g/dl within the first six months of initiation of
ART. In our study, some patients did not have any other
Hb measurement within six months of ART initiation. In
order to minimize the bias from patients who died or
were lost to follow up, we made every effort to character-
ize these patients with additional chart reviews to identify
any symptoms of severe anaemia at the time of death or
last study visit, in addition to other co-morbid conditions.
Statistical analysis
We calculated the mean and standard deviation or med-
ian and interquartile range (IQR) of baseline characteris-
tics and the change in Hb over the first six months after
ART initiation. We used c
2 tests to compare propor-
tions and Student’s t-test and Mann-Whitney test were
used to compare continuous data. We used multivari-
able logistic regression to identify factors associated with
development of early severe anaemia and included all
patients who had an Hb test recorded within six months
of commencement of ART. Patients with unresolved
baseline severe anaemia were included in the multivari-
able analysis.
Baseline factors at AZT commencement included gen-
der and age, body mass index (BMI), CD4 cell count,
mean corpuscular volume (MCV), Hb, and ART regi-
men. Tuberculosis (TB) after ART initiation but before
the development of anaemia was considered as a poten-
tial risk factor. Multivariable models were fitted using
forward stepwise selection and variables with p < 0.10
or previously described risk factors being included in
the model. Variables with multiple categories were
included if overall tests for trend in heterogeneity were
significant (p < 0.10).
In a separate analysis, we attempted to include all
patients with missing Hb data within their first six
months by imputing a “second” Hb measurement using
chained equations (MICE), which involve creating sample
missing values conditional on the distribution of remain-
ing predictors in the multivariable model. We assumed
that the Hb data in this group of patients was missing at
random and carried out five rounds of multiple imputa-
tions; a combined dataset using Rubin’sr u l ew a st h e n
analyzed [20]. We compared the results from the imputa-
tion with those from the model without imputation. All
the analyses were performed using STATA software,
version 10.0 (STATA corporation, Texas, USA).
Ethical approval for the use of all routinely collected
data for the care and management of HIV-positive
patients at the Infectious Diseases Institute was obtained
from the Makerere University Research and Ethics
Committee and the Uganda National Council of Science
and Technology.
Results
Baseline characteristics
We studied the data recorded for 5494 patients from our
clinic who had baseline Hb measurements and were
initiated on an AZT- or d4T-containing ART regimen
between January 2004 and January 2009 (See additional
file 1: description of patients at the Infectious Diseases
Institute). The majority, 3264 (59.4%), were initiated on
d4T-containing regimens. Of the 5494, 821 (15%) had
baseline anaemia (Hb ≤9.5g/dL); 237 (28.9%) of the 821
anaemic patients were initiated on AZT. Among the 296
(5.4%) of the total 5494 patients who had baseline severe
anaemia, 65 (22%) were started on an AZT-containing
regimen, and 231 (78%) on d4T (p < 0.001) (See additional
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antiretroviral therapy).
Severely anaemic patients were more likely to be
WHO Stage III-IV rather than I-II (252 (85%) vs. 44
(14.9%), p < 0.001), and were more likely to be female
(208 (70%) vs. 88 (29.7%), p < 0.001). No blood transfu-
sions were given to the patients with severe baseline
anaemia. In our settings, only severely symptomatic
anaemic patients are given blood transfusions, and they
are not initiated on ART. Of the 296 patients with base-
line severe anaemia, 65 (22%) were given haematinics
(folic acid 5 mg and/or ferrous sulphate 200 mg) within
three months of ART initiation; 52 were given both folic
acid and ferrous sulphate; 12 were given only ferrous
sulphate; and one patient was only given folic acid.
Similar proportions of patients given haematinics were
observed in the AZT and d4T group of patients: 13 of
65 (20%) versus 52 of 231 (22%), p = 0.665. Forty-three
(66%) of those who were given haematinics had a low
MCV (<80fl).
Changes in haemoglobin after ART
The baseline characteristics of the 3105 patients who
had a second Hb measurement within six months after
ART initiation are listed in Table 1. Patients with base-
line anaemia had a larger increase in Hb within the first
six months compared with those who were non-anaemic
(median change g/dL [IQR]; 2.9 [1.7- 4.6] vs. 0.7 [-0.2-
1.7], p < 0.0001). When we compared the median g/dL
[IQR] changes in Hb for patients with baseline anaemia
initiated on d4T and those on AZT, patients on d4T
had a larger increase in Hb: 3.1 [1.8- 4.9] versus 2.5
[1.4- 5.0], p < 0.012). Median g/dL [IQR] changes within
six months of ART initiation in patients with baseline
Hb ≥11 g/dl was 0.3 [0.6- 1.2]; 8-11 g/dL was 1.5 [0.5-
2.5], and <8 g/dL was 3.55 [1.7- 5.3], p < 0.024.
Among patients with baseline severe anaemia, the
65% of those who were started on either regimen
(AZT- and d4T-containing regimens) had increases in
Hb to >9.5 g/dL. Figure 1 shows the change in Hb that
occurs as a result of ART initiation by baseline regi-
men. When we compared the median Hb increases in
patients with baseline severe anaemia who were
initiated on d4T versus AZT, there were similar
increases in Hb: (median g/dL [IQR]: 3.7 [1.7- 5.4] vs.
3.1 [1.4- 4.5], p = 0.203).
In the study, 3105 had second Hb measurements within
six months on ART and of these, 109 (3.5%) had early
severe anaemia (Hb ≤8 g/dl). Thirty (27.5%) of the patients
with early severe anaemia had baseline severe anaemia and
these had unresolved baseline severe anaemia. Only four
of these patients with unresolved baseline anaemia had
been initiated on AZT.
Predictors of early severe anaemia
The univariate analysis showed that baseline severe anae-
mia Hb (≤8 g/dL), low MCV (<80fL), and having had a
new TB episode after ART initiation were independently
associated with increased risk of early severe anaemia
(Table 2). The multivariable analysis showed that TB OR
3.69 (95% CI 1.64 - 8.32), MCV <80fL OR 1.60 (95% CI
1.01 - 2.52) and baseline severe anaemia OR 5.27 (95% CI
3.00 - 9.26) were significantly associated with early severe
anaemia. Including AZT in the initial ART regimen was
not associated with an increased risk of early severe anae-
mia compared with initiation of a d4T-based regimen
OR1.33 (95% CI 0.85 - 2.07), when adjusted for age, gen-
der, BMI, WHO stage, baseline CD4 T cell count, base-
line Hb, MCV, and incident TB.
In a multivariable analysis stratified by gender, we
found that a baseline severe anaemia OR 5.79 (95% CI
1.67 - 20.00), p = 0.006, and incident TB OR 5.68 (95%
CI 1.89 - 17.14), p = 0.002, were associated with early
severe anaemia in the male patients. In the female
patients, the multivariable analysis showed again that
incident TB OR 5.52 (95% CI 2.41-12.67), p < 0.0001,
and baseline severe anaemia OR 5.51 (95% CI 2.86-
10.60), p < 0.0001, were significantly associated with
early severe anaemia. In addition, advanced WHO clini-
cal Stage III-IV OR 2.08 (95% CI 1.01 - 3.97), p = 0.046,
was also associated with severe anaemia. In this analysis,
AZT was similarly not associated with early severe anae-
mia in both men and women.
Outcomes of patients with baseline anaemia
Among patients with baseline anaemia who had second
Hb tests, 232 (96%) of the 241 patients started on a
d4T-containing regimen had an increase in Hb and nine
(4%) had a decrease. Among the 92 patients started on
an AZT-containing regimen who had baseline anaemia
and at least one post-ART initiation Hb test, 85 (92.4%)
h a da ni n c r e a s ei nH ba n df i v e( 5 . 4 % )h a dad e c r e a s e .
When we consider only the subset of these patients who
had severe baseline anaemia, of 111 patients started on
d4T, 99 (89.2%) had an increase in Hb and 12 (10.8%)
had a decrease. Of 35 started on AZT, 34 (97%) had an
increase and only one (3%) had a decrease.
In the first six months, changes were made to the
regimens of 134 patients; the switch rate per 100 person
years at risk was 3.5 (95% CI 2.9 - 4.1). Overall, the rate
per 100 person years at risk of regimen switching across
baseline regimen (d4T vs. AZT) was not different (3.32
(95% CI 2.65 - 4.17) vs. 3.69 (95% CI 2.85 - 4.77), p =
0.749 (Figure 2). Switching due to toxicities was the
main reason for treatment change in the first six
months after initiation, occurring in 82 (61.2%) of 134;
only one patient with baseline severe anaemia who
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switch because of persistent or worsened anaemia.
Characteristics of patients who did not have at least one
Hb measurement
The 3105 patients had second Hb measurements within
the first six months of ART initiation. Because exclusion
of patients with only one Hb measurement could have
excluded the patients with life-threatening anaemia and/
or death after AZT initiation, we reviewed records for
the 2389 patients who had only one Hb measurement at
baseline and no additional Hb measurement during their
first six months on ART. Of these, 2054 (86%) were still
in active care at six months, and 335 (14%) were inacti-
vated in the first six months of ART. Of the 335 patients,
154 (46%) had died, 160 (48%) had been transferred to
other care providers, and 21 (6%) were lost to therapy;
their baseline Hb was (median [IQR]) 11.4 g/dL (10.2,
12.6). Sixty-five (19.4%) had a baseline Hb <9.5 g/dL
while 27 (6.6%) had baseline severe anaemia; 19 died and
17 were initiated on d4T. The median (IQR) Hb at start
of ART for the patients who died was 10.6 (9.1-11.8).
Anaemia clearly contributed to death in 11 of the 154
patients who died within six months of ART initiation,
and five of these were initiated on d4T.
When we compared the baseline characteristics of
patients who had only one Hb measurement within six
months with those without second Hb tests in the six
months after ART, the latter had lower median CD4
cells/mm
3 counts (101 versus 94, p = 0.008), more had
started on AZT (46% versus 37%, p < 0.001), and they
were less likely to be female (63% versus 67%, p =
0.006). In a multivariable analysis using the combined
data set from the MICE procedure, which included all
patients in the model after the imputation of a second
Hb within six months for those patients without, we
found that AZT was still not predictive of early severe
anaemia; OR 1.43 (95% CI 0.92 - 2.21).
Table 1 Baseline characteristics of patients with second haemoglobin measurement in first six months of ART
initiation
Characteristic All patients (n = 3105) Patients with early severe anaemia (n = 109)
Gender
Female 2065 (67%) 80 (73%)
Male 1040 (23%) 29 (26%)
Age (yrs) median (IQR) 36 (31,42) 37 (30,41)
BMI (kg/m
2) median
(IQR)* 20 (18,23) 18 (17,22)
WHO stage
I-II 937 (30%) 25 (23%)
III- IV 2168 (70%) 84 (76%)
CD4 T cell count,
Median (IQR) 101 (33, 173) 65 (21,144)
200+ 426 (14%) 12 (11%)
50-199 1589 (51%) 47 (43%)
<50 942 (30%) 44 (40%)
Missing 148 (5%) 6 (6%)
HB g/dL
≥8 2959 79
<8 146 30
MCV, median (IQR) 84 (79,90) 79 (74,86)
≥80fL 2225 54
<80fL 880 55
TB
No 3035 (98%) 93 (85%)
Yes 70 (2%) 16 (15%)
Regimen
d4T-containing 1965 65
AZT-containing 1140 44
BMI = body mass index, HB = hemoglobin, MCV = mean corpuscular volume, IQR = interquartile range, TB = tuberculosis, ART = antiretroviral therapy, d4T =
stavudine, AZT = zidovudine, OR = odds ratio.
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Figure 1 Haemoglobin changes after ART initiation in patients
with baseline severe anemia. Change in Hb in first six months
after ART initiation among patients initiated on d4t and with
baseline severe anaemia (Hb ≤8 g/dL) and a second Hb
measurement within six months of ART initiation.
Table 2 Predictors of early severe anaemia in the first six months of ART initiation
Characteristic Univariate OR (95% CI) P-value Adjusted OR (95% CI) P-value
Gender
Male 0.71 (0.46-1.09) 0.122
Age (yrs) median (IQR) 0.97 (0.87-1.09) 0.662
BMI (kg/m
2) median (IQR) 0.89 (0.84-0.96) 0.001 0.94 (0.88-1.01) 0.054
WHO stage
I-II 1.00 1.00
III-IV 1.47 (0.93-2.31) 0.095 1.23 (0.72-2.09) 0.444
CD4 T cell count,
Median (IQR) 0.057 0.606
a
200+ 1.00 1.00
50-199 1.05 (0.55-2.00) 0.878 0.84 (0.41-1.72) 0.631
<50 1.69 (0.88-3.23) 0.113 1.11 (0.53-2.32) 0.782
HB g/dL,
>8 1.00 1.00
≤8 9.43 (5.95-14.93) <0.0001 5.27 (3.00-9.26) <0.0001
MCV, median (IQR)
≥80 1.00 1.00
<80 2.68 (1.82-3.93) <0.0001 1.60 (1.01-2.52) 0.045
TB episode
No 1.00 1.00 0.002
Yes 8.96 (4.46-18.02) <0.0001 3.69 (1.64-8.32)
Regimen
d4T 1.00 1.00 0.209
AZT 1.17 (0.79-1.73) 0.421 1.33 (0.85-2.07)
Note: a - p value from overall test for trend in heterogeneity BMI = body mass index, HB = hemoglobin, MCV = mean corpuscular volume, IQR = interquartile
range, TB = tuberculosis, ART = antiretroviral therapy, d4T = stavudine, AZT = zidovudine, OR = odds ratio.
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Figure 2 Proportion discontinuing a d4T- or AZT- based
regimen with six months of ART initiation. Patients who were
initiated on an AZT-containing regimen (n = 2230) are denoted
with a dotted line; those initially on d4T-containing regimen (n =
3264) are denoted with a dashed line.
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In our study, we found baseline anaemia in 15% of the
patients who had Hb measurements within three months
of ART initiation; one-third of the anaemic patients (5%
overall) had severe baseline anaemia. Our results are
similar to those seen in other sub-Saharan African cen-
tres that have initiated patients on ART, where the pro-
portion of patients with baseline anaemia ranged from
12% to 18.2% [9], and the proportion with severe baseline
anaemia ranged from 2% to 10% [21]. Results from the
Development of Antiretroviral Therapy in Africa study
showed that patients with BMI <18 kg/m
2 had a higher
risk of developing Grade 4 (Hb <6.5 g/dL) anaemia [9].
A study in India showed that TB was also significantly
associated with anaemia [22].
In our study, patients with baseline anaemia were more
likely to present with TB after ART initiation suggesting
that they may have had occult, unrecognized active dis-
ease or were sick at baseline and had not fully recovered
and remained more susceptible. Among the 3105 patients
with second Hb measurements, 70 had incident TB epi-
sodes before acquiring early severe anaemia; TB was
associated with an increased risk for early severe anae-
mia, which suggested that anaemia was likely to be
related to sub-clinical TB.
Although anaemia was prevalent in our population
prior to the initiation of ART, ART led to an increase in
Hb in the majority of our patients. This finding confirms
data from studies in South Africa [12], Uganda and
Zimbabwe [9], which report 0.28 g/dL and 0.6 g/dL
median increases in Hb measured six months after ART
initiation. In our study, the greatest Hb increases were
realized in patients with the lowest baseline Hb levels,
and only 3.5% developed early severe anaemia in the first
six months of ART.
The most important risk factors for having early
severe anaemia, in patients initiated on ART were a pre-
existing diagnosis of TB, a low MCV, and baseline
severe anaemia. In this resource-limited setting, AZT
was not associated with an increased risk for early
severe anaemia after highly active ART despite its
k n o w nt o x i c i t yw h e nu s e da sas i n g l ea g e n ti nt h ep r e -
ART era. This finding has been previously described in
the developed world [7,11].
In a sub-analysis of those patients who were initiated
on AZT with a baseline severe anaemia, only one patient
( o f6 5 )h a dt ob es w i t c h e df r o mA Z Tb e c a u s eo fp o s t -
ART severe anaemia. This patient, with a baseline and
nadir Hb of 6.8, was switched to d4T/3TC/EFV within
two weeks of ART initiation and also developed a new
TB episode, and was later transferred to another HIV
treatment centre. In contrast, 12 of the 111 patients
initiated on d4T developed worsening anaemia. The
reasons that patients were initiated on AZT despite base-
line severe anaemia are unknown and there may have
been clinicians’ reasons to start ART.
In a study conducted by Hoffman and colleagues in
South Africa, none of the 11 subjects with Hb between
7.4 and 9.9 g/dL (who were not eligible to receive AZT,
b u tw e r ep r e s c r i b e di t )d e v e l o p e ds e v e r ea n a e m i a[ 1 2 ] .
In the Treat Asia HIV Observational Database study in
Asia, among patients started on an AZT-containing
regimen, older age, lower BMI (<21 kg/m
2), baseline
anaemia (Hb <10 g/dL) and concurrent TB were asso-
ciated with anaemia after ART, although this study did
not examine AZT as a risk factor in all patients initiat-
ing ART [23].
The association of anaemia with concurrent TB has
been shown in two studies: ours and that of Huffam et
al [21]. These studies emphasize the importance of
treating co-morbid diseases that can contribute to anae-
mia. Timely identification and treatment of TB should
be accomplished through intensified case finding at the
time of ART initiation [24]. Finally, both low MCV [8]
and baseline anaemia [9,10,25] have been previously
reported as risk factors for the development of severe
anaemia in other studies that were conducted in the
post-ART era and that corroborate our data.
In the univariate analysis, low BMI was also associated
with an increased risk for post-ART anaemia, although
this was not an independent risk factor in our multivari-
able analysis since it was confounded by other factors,
including presence of TB and the very low baseline Hb.
Other published reports showed BMI to be a risk factor
for early severe anaemia [7], which may be a surrogate
marker for patients who are more severely immunocom-
promised or with limited iron stores and protein to
make Hb. Interestingly, a report from Thailand showed
that switching to AZT from a d4T-based regimen after
immune reconstitution is associated only rarely with
AZT-induced anaemia [26]. Improvement of immuno-
suppression prior to switches to AZT-containing regi-
mens, as evidenced by increased BMI and increased
CD4 T cell counts, further decreased the risk of AZT-
induced anaemia [27].
Although our study is based on data from a large pro-
spective cohort that has been followed continuously
since the beginning of ART rollout in Uganda, there are
some limitations with respect to the generalizability of
our conclusions. Patients who are initiating ART at pre-
sent may have less immunosuppression (higher CD4
counts) than the cohort we analyzed. This difference
may decrease the risk of AZT-induced anaemia [28].
In addition, the analysis only included patients who had
both a baseline Hb measurement and at least one other
measurement within six months of ART initiation.
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were lost to follow up, we made every effort to character-
ize these patients with additional chart reviews and found
that only 11 patients had symptoms of severe anaemia at
the time of death in addition to other co-morbid
conditions.
Conclusions
In our cohort, the overwhelming majority of patients
who initiated ART with any of the first-line regimens
recommended in Uganda had improvements in Hb in
the first six months. The development of early severe
anaemia after ART initiation was most closely associated
with baseline severe anaemia and incident TB infection
and was not associated with the use of an AZT-contain-
ing regimen. Although we would conclude that AZT is
relatively safe when compared to d4T, even in patients
with severe baseline anaemia, if alternative regimens
known to have even lower haematologic toxicity are
available and affordable, they may be preferable.
Still, our study, taken together with other available
data, shows that ART should not be withheld from
patients with severe anaemia if regimens containing AZT
are either the only ones available or are preferred for
other reasons. Our data suggest that setting a lower limit
Hb, specifically Hb ≤8 g/dL, as a determinant of whether
AZT-containing regimens should be prescribed may not
be warranted. Low BMI (<18 kg/m
2)a n dl o wM C V
(<80fL) may be more useful in predicting which patients
are at highest risk for AZT-induced anaemia. Finally,
intensified TB screening of anaemic patients is war-
ranted, as well as vigilance for TB after ART initiation.
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